Susceptibility pattern of extended spectrum ß-lactamase producing isolates in various clinical specimens

Journal of the College of Physicians and Surgeons Pakistan

Volumn 21, Issue 6, 2011, Pages 342-346

  Roshan, Muhammad ^a   Ikram, Aamer ^b   Mirza, Irfan Ali ^a   Malik, Nasrullah ^a   Abbasi, Shahid Ahmad ^a   Alizai, Shehla Ambreen ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

^b Malir National University of Medical Sciences   (Pakistan)

Author keywords

Antibiotic susceptibility; Combination disc synergy; ESBLs; Gram negative rods

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; NITROFURONTOIN; PIPEMIDIC ACID; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULPERAZON; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CHILD; CITROBACTER FREUNDII; CITROBACTER KOSERI; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; INFANT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MORGANELLA MORGANII; NONHUMAN; PANTOEA AGGLOMERANS; PRESCHOOL CHILD; PROTEUS MIRABILIS; PROTEUS VULGARIS; PROVIDENTIA ALCALIFICIANS; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SERRATIA MARCESCENS; SERRATIA ODERIFERA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK ASSESSMENT; YOUNG ADULT;

EID: 79958824577     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8.
2. Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum β-lactamases among enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol 2006; 24:208-11.
3. Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N. Extended spectrum β-lactamases among gram negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis 2005; 5:86.
4. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 18th informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute; 2008.
5. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In-vitro activity of tigecycline against multiple-drug resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek Hospitals. Antimicrob Agent Chemother 2006; 50:3166-9.
6. Ahmed A, Zafar A, Mirza S. Antimicrobial activity of tigecycline against nosocomial pathogens in Pakistan: a multicenter study. J Pak Med Assoc 2009; 59:240-2.
7. Zaman G, Karamat AK, Abbasi AS, Rafi S, Ikram A. Prevalence of extended spectrum beta-lactamase producing Entero-bacteriaceae in nosocomial isolates. Pak Armed Forces Med J 1999; 49:91-6.
8. Rahman MM, Haq JA, Hossain MA, Sultana R, Islam F, Islam AH. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an urban hospital in Dhaka, Bangladesh. Int J Antimicrob Agents 2004; 24:508-10.
9. Shah AA, Hasan F, Ahmed S, Hameed A. Extended spectrum beta-lactamases in Enterobacteriaceae: related to age and gender. New Microbiol 2002; 25:363-6.
10. Mirza SH, Khurshid U, Wiqar MA, Salman M. CTX-M ESBL enzyme in Escherichia coli from urology patients in Rawalpindi, Pakistan. J Pak Med Assoc 2006; 56:576-8.
11. Feizabadi MM, Etemadi G, Yadegarinia D, Rahmati M, Shabanpoor S, Bokaei S. Antibiotic resistance patterns and frequency of extended-spectrum β-lactamase-producing isolates of Klebsiella pneumoniae in Tehran. Med Sci Monit 2006; 12:362-5.
12. Marra AR, Wey SB, Castelo A, Gales AC, Cal RG, Filho JR, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6:24.
13. Carrer A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agent Chemother 2008; 52:2950-54. Epub 2008 Jun 2.
14. Groebner S, Linke D, Schuetz W, Fladerer C, Madlung J, Autenrieth IB, et al. Emergence of carbapenem-non-susceptible extended-spectrum-beta-lactamase (ESBL)-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany. J Med Microbiol 2009; 58:912. Epub 2009 Jun 5.
15. Jabeen K, Zafar A, Hassan R. Frequency and sensitivity pattern of extended spectrum beta-lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc 2005; 55:436-9.
16. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005; 52:323-9.
17. Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007; 57:341-4. Epub 2006 Dec 1.
18. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum ß-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201:237-41.
19. Al-Zahran JA, Akhtar N. Susceptibility patterns of extended spectrum ß-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolated in a teaching hospital. Pak J Med Res 2005; 44:64-7.
20. Gavin PJ, Suseno MT, Thomson RB Jr, Gaydos JM, Pierson CL, Halstead DC, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006; 50:2244-7.
21. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-94.
22. Ramesh N, Sumathi CS, Balasubramanian V, Pallanipan KR, Kannan VR. Urinary tract infection and antimicrobial susceptibility pattern of extended spectrum beta-lactamase producing clinical isolates. Adv Biol Res 2008; 2:78-82.
23. Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic co-resistance in extended-spectrum-beta-lactamase-producing enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2695-9.
24. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29:62-5.